Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
Top Page
Olema Pharmaceuticals
(NASDAQ:OLMA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$16.50
▲(3.58% Upside)
Action:ReiteratedDate:03/17/26
The score is held down primarily by weak financial performance driven by no revenue, widening losses, and rising cash burn, alongside bearish technical momentum. A low-debt balance sheet and a positive strategic update support the outlook, but do not offset the near-term funding and execution risks.
Positive Factors
Low Leverage / Strong Balance Sheet
Minimal debt and sizable equity provide structural financial flexibility, reducing solvency risk and enabling the company to fund clinical programs or pursue partnerships without immediate pressure from creditors. This balance-sheet strength supports strategic optionality over the next several quarters.
Negative Factors
Pre-revenue with Widening Losses
As a clinical-stage, pre-revenue company, Olema lacks product cash flow and has seen losses widen materially. Sustained negative earnings compress returns on equity and heighten dependence on external capital; absent clinical success, this undermines long-term financial sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Minimal debt and sizable equity provide structural financial flexibility, reducing solvency risk and enabling the company to fund clinical programs or pursue partnerships without immediate pressure from creditors. This balance-sheet strength supports strategic optionality over the next several quarters.
Read all positive factors
Olema Pharmaceuticals (OLMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.40B
Dividend YieldN/A
Average Volume (3M)1.95M
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue GrowthN/A
EPS Growth17.23%
CountryUS
Employees96
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.50
Shares Outstanding87,156,960
10 Day Avg. Volume898,786
30 Day Avg. Volume1,953,985
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.26K
Enterprise Value/Ebitda-7.68
Forecast
1Y Price Target
$42.50Price Target Upside166.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$2.05M
Olema Pharmaceuticals Business Overview & Revenue Model
Company Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and...
How the Company Makes Money
null...
Olema Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -178.21M | -141.87M | -104.58M | -106.63M | -71.33M |
| Net Income | -162.45M | -129.47M | -96.66M | -104.79M | -71.10M |
Balance Sheet | |||||
| Total Assets | 533.43M | 450.98M | 276.94M | 215.65M | 295.94M |
| Cash, Cash Equivalents and Short-Term Investments | 505.44M | 434.09M | 261.81M | 204.42M | 287.25M |
| Total Debt | 1.19M | 1.43M | 2.42M | 2.56M | 3.29M |
| Total Liabilities | 54.87M | 42.02M | 23.05M | 18.10M | 11.38M |
| Stockholders Equity | 478.56M | 408.96M | 253.90M | 197.55M | 284.57M |
Cash Flow | |||||
| Free Cash Flow | -146.72M | -104.51M | -83.73M | -82.43M | -52.27M |
| Operating Cash Flow | -146.72M | -104.35M | -83.73M | -82.06M | -50.69M |
| Investing Cash Flow | -155.76M | -93.53M | -4.85M | 91.48M | -275.44M |
| Financing Cash Flow | 211.30M | 268.82M | 133.41M | 476.00K | 1.39M |
Olema Pharmaceuticals Technical Analysis
Positive
15.93
Price Trends
19.57
Negative
23.17
Negative
15.10
Positive
Market Momentum
-0.93
Negative
45.60
Neutral
77.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OLMA, the sentiment is Positive. The current price of 15.93 is above the 20-day moving average (MA) of 14.92, below the 50-day MA of 19.57, and above the 200-day MA of 15.10, indicating a neutral trend. The MACD of -0.93 indicates Negative momentum. The RSI at 45.60 is Neutral, neither overbought nor oversold. The STOCH value of 77.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OLMA.
Olema Pharmaceuticals Risk Analysis
Olema Pharmaceuticals disclosed 89 risk factors in its most recent earnings report. Olema Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Olema Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $220.93M | 8.71 | 14.25% | ― | 37798.31% | ― | |
54 Neutral | $730.57M | -5.60 | -1065.47% | ― | 96.83% | -61.92% | |
52 Neutral | $931.05M | -12.74 | -43.61% | ― | -100.00% | -28.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $692.06M | -9.53 | -14.25% | ― | ― | ― | |
47 Neutral | $1.40B | -13.39 | -42.90% | ― | ― | 17.23% | |
41 Neutral | $96.11M | -3.72 | 264.70% | ― | -58.17% | -116.24% |
* Healthcare Sector Average
OLMA
Olema Pharmaceuticals
15.93
11.87
292.36%
MGTX
Meiragtx Holdings
9.63
4.15
75.73%
ARVN
Arvinas Holding Company
10.58
3.18
42.97%
GOSS
Gossamer Bio
0.40
-0.41
-50.74%
KROS
Keros Therapeutics
11.15
-1.59
-12.48%
CMPX
Compass Therapeutics
5.20
3.48
202.33%
Olema Pharmaceuticals Corporate Events
Executive/Board Changes
Olema Pharmaceuticals CFO Departs; CEO Assumes Interim Role
Neutral
Jan 30, 2026
On January 30, 2026, Olema Pharmaceuticals, Inc. announced that Chief Operating and Financial Officer Shane Kovacs departed the company on that date to pursue new opportunities, though he will remain as a consultant through August 1, 2026 under a ...
Business Operations and Strategy
Olema Highlights Palazestrant Strategy in New Investor Presentation
Positive
Jan 12, 2026
On January 12, 2026, Olema Pharmaceuticals posted an investor presentation on its website outlining its strategy to transform the treatment paradigm for ER+/HER2- metastatic breast cancer, emphasizing the blockbuster potential of palazestrant in f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.